Efficacy and Safety of Mavacamten and Aficamten in Obstructive and Non-obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis

By afschroeder • February 5, 2026

Ibrahim M, Kashif A, Arfin SMW, Mubeen M, Zafar A, Balach R, Musani MH, Greene SJ, Fonarow GC, Sohail MU. Efficacy and Safety of Mavacamten and Aficamten in Obstructive and Non-obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. Crit Pathw Cardiol. 2026 Jan 30. doi: 10.1097/HPC.0000000000000418. Epub ahead of print. PMID: 41641607.

Tags: aficamten, cardiac myosin inhibitors, Cardiology/Epi, Hypertrophic cardiomyopathy, Left ventricular outflow tract gradient, Mavacamten, meta-analysis, Publications, Randomized Controlled Trials

The Cost-Effectiveness Evolution of Cardiovascular Care

Fonarow GC, Navar AM, Yancy CW. The Cost-Effectiveness Evolution of Cardiovascular Care. JAMA Cardiol. 2026 Feb 4. doi: 10.1001/jamacardio.2025.5240. Epub ahead of print. PMID: 41637084.

Association of Recurrent Atrial Fibrillation With Subsequent Kidney Function Decline in Adults Receiving Rhythm Control Therapy

Bansal N, Zelnick LR, Tabada G, An J, Harrison TN, Lee MS, Zheng C, Lidgard B, Singer DE, Garcia E, Go AS. Association of Recurrent[...]

Late-in-life treadmill-training mitigates gut microbiome imbalances and cardiovascular disease risk in mice

Cho JM, Park SK, Satheesh Babu AK, Mookherjee S, Hansen M, Petersen C, Zhong Y, Jalili T, Robeson MS, Whankade UD, Anandh Babu PV, Symons[...]